Concepedia

B Fryer

BF

Statistics

Publications

3

Citations

564

H-Index

3

Active since

1997

Affiliations

Cleveland Clinic(Current)

Pathways Behavioral Services

B Fryer is an author at Cleveland Clinic specializing in medicine, pathology, and oncology.

Top concepts

Publications per year

1997–2000

3

Publications

3

Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.

Gary A. Piazza, A K Rahm, T S Finn et al. · PubMed · 1997 · 354 citations

, , +17

Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.

Rosalind van Stolk, G D Stoner, William L. Hayton et al. · PubMed · 2000 · 105 citations

, , +12

Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous Polyposis

G D Stoner, G. T. Budd, Ram Ganapathi et al. · Advances in experimental medicine and biology · 1999 · 105 citations

, , +3

1–3 of 3